BKBhargav Kanuparthi

Bhargav Kanuparthi

*This is an algorithmically generated author record based on publicly available information.

Bhargav Kanuparthi has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    DeepRNAi: Predicting on- and off-target siRNA activity and establishing a benchmark

    by Nicolas Y. Masse, Tammy T.Y. Lau, Jeff Wintersinger, Mykhaylo Slobodyanyuk, Roujia Li, Vivian S. Chu, Helen Zhu, Bhargav Kanuparthi, Jonathan La, Brodie Fischbacher, et al.

    Small interfering RNAs (siRNAs) silence target genes through RISC-mediated hybridization and cleavage, but can silence unintended transcripts and cause toxicity or complicate regulatory approval. In drug development, empirical assessment by qPCR and RNA-seq is slow, forces early candidate prioritization, and is limited by available species- and genome-appropriate cell models. While extensive empirical screening remains standard practice, there is a significant opportunity for modern AI methods to change this paradigm. We introduce DeepRNAi, a deep learning model that accurately predicts on- and off-target knockdown from siRNA and mRNA sequence. Trained on 16 million siRNA-transcript pairs from 2,031 siRNAs designed to interrogate known siRNA failure modes, and incorporating transcript context from biological foundation models, DeepRNAi is the first in silico method that approaches experimental accuracy. It generalizes across cell models, transcripts, genomes and species, and in a small study distinguishes approved therapeutics from hepatotoxic candidates. The value of DeepRNAi for prioritizing better candidates up front improving likelihood of success later in development is evidenced by a genome-wide survey of 24.4 million siRNAs targeting 7,946 genes, which indicates that 90.1% of the 100 most potent siRNAs have at least some off-target concerns. To support the community, we are publishing a training and benchmark dataset containing 1.84 million siRNA-transcript pairs from 240 siRNAs.

  • Open Access

    Sequence based prediction of cell type specific microRNA binding and mRNA degradation for therapeutic discovery

    by Bhargav Kanuparthi, Sara E. Pour, Scott D. Findlay, Omar Wagih, Jahir M. Gutierrez, Rory Gao, Jeff Wintersinger, Junru Lin, Martino Gabra, Emma Bohn, et al.

    MicroRNAs and RNA binding proteins are crucial elements of post-transcriptional gene regulation, which governs the fate of mRNA molecules in the cell. However, the landscape of these regulatory interactions, particularly across different mammalian cell types, remains underexplored. We describe REPRESS, a deep learning model that predicts cell-type-specific microRNA binding and mRNA degradation directly from RNA sequence. REPRESS was trained on AGO2-CLIP, miR-eCLIP and Degradome-Seq data profiling millions of microRNA binding and mRNA degradation sites across multiple cell types in human and mouse. It reveals biology that other state-of-the-art methods did not, such as identifying repressive non-canonical miRNA target sites and decoding the regulatory effects of sequence context and miRNA binding site multiplicity. REPRESS outperforms other advanced methods and neural architectures on a comprehensive suite of seven orthogonal tasks, including identifying genetic variants that affect microRNA binding, predicting out-of-distribution data from massively parallel reporter assays, and predicting canonical and non-canonical miRNA mediated repression. To demonstrate the general utility of REPRESS, we show that it provides insights into novel biology and the design of RNA therapeutics. Code is available at : https://github.com/deepgenomics/repress


  • Open Access

    An RNA foundation model enables discovery of disease mechanisms and candidate therapeutics

    by Albi Celaj, Alice Jiexin Gao, Tammy T.Y. Lau, Erle M. Holgersen, Alston Lo, Varun Lodaya, Christopher B. Cole, Robert E. Denroche, Carl Spickett, Omar Wagih, et al.

    Accurately modeling and predicting RNA biology has been a long-standing challenge, bearing significant clinical ramifications for variant interpretation and the formulation of tailored therapeutics. We describe a foundation model for RNA biology, “BigRNA”, which was trained on thousands of genome-matched datasets to predict tissue-specific RNA expression, splicing, microRNA sites, and RNA binding protein specificity from DNA sequence. Unlike approaches that are restricted to missense variants, BigRNA can identify pathogenic non-coding variant effects across diverse mechanisms, including polyadenylation, exon skipping and intron retention. BigRNA accurately predicted the effects of steric blocking oligonucleotides (SBOs) on increasing the expression of 4 out of 4 genes, and on splicing for 18 out of 18 exons across 14 genes, including those involved in Wilson disease and spinal muscular atrophy. We anticipate that BigRNA and foundation models like it will have widespread applications in the field of personalized RNA therapeutics.